---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-096633"
form_type: "8-K"
ticker: null
cik: "0001733413"
company_name: "TFF Pharmaceuticals, Inc."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:37:47.111316+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Positive interim Phase 2 data for TFF VORI and TFF TAC; company to accelerate to registration-enabling studies

## Summary
- All five TFF VORI patients achieved clinical and mycologic responses; no all-cause mortality or discontinuations due to AEs.
- All four TFF TAC patients transitioned from oral tacrolimus with reduced blood levels; no acute rejection; kidney function maintained.
- Company plans to accelerate initiation of registration-enabling studies for both TFF VORI and TFF TAC.
- 1-for-25 reverse stock split effective December 19, reducing shares from ~59M to ~2.4M.

## SEC filing metadata
- accession: 0001213900-23-096633
- form_type: 8-K
- cik: 0001733413
- company_name: TFF Pharmaceuticals, Inc.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/0001213900-23-096633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/ea190285-8k_tffpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-096633
- JSON: https://secwatch.observer/filing/0001213900-23-096633.json
- Plain text: https://secwatch.observer/filing/0001213900-23-096633.txt

## Key facts
- Governance Changes
  TFF Pharmaceuticals, Inc.: Filed Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2023-12-19).
  - Change: charter amendment
  - Effective: 2023-12-19
  source text: On December 18, 2023, TFF Pharmaceuticals, Inc. (the “Company”) filed with the Delaware Secretary of State a Certificate of Amendment (“Amendment”) to its Second Amended and Restated Certificate of Incorporation to effect a one for twenty-five (25) reverse stock split (“Reverse Split”) of its issued and outstanding shares of common stock. The effective time of the Reverse Split is 12:01 AM ET on December 19, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/0001213900-23-096633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.